Zometa is a brand name of zoledronic acid, approved by the FDA in the following formulation(s):
ZOMETA (zoledronic acid - injectable; iv (infusion))
Manufacturer: NOVARTIS
Approval date: March 7, 2003
Strength(s): EQ 4MG BASE/5ML [RLD]
Manufacturer: NOVARTIS
Approval date: June 17, 2011
Strength(s): EQ 4MG BASE/100ML [RLD]
Has a generic version of Zometa been approved?
No. There is currently no therapeutically equivalent version of Zometa available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zometa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Substituted alkanediphosphonic acids and pharmaceutical use
Patent 4,939,130
Issued: July 3, 1990
Inventor(s): Jaeggi; Knut A. & Widler; Leo
Assignee(s): Ciba-Geigy Corporation
Alkanediphosphonic acids, in particular heteroarylalkanediphosphonic acids of formula ##STR1## wherein R.sub.1 is a 5-membered heteroaryl radical which may be fused with benzene or cyclohexene nuclei and which contains, as hetero atoms, 2 to 4 N-atoms or 1 or 2 N-atoms as well as 1 O- or S-atom, and which is unsubstituted or C-substituted by lower alkyl, phenyl or phenyl which is substituted by lower alkyl, lower alkoxy and/or halogen, or by lower alkoxy, hydroxy, di-lower alkylamino, lower alkylthio and/or halogen, and/or is N-substituted at a N-atom which is capable of substitution by lower alkyl, lower alkoxy and/or halogen, and R.sub.2 is hydrogen, hydroxy, amino, lower alkylthio or halogen, and salts thereof, have regulatory action on calcium metabolism and can be used as medicaments for the treatment of diseases associated with impairment of calcium metabolism. The compounds are obtained for example by converting, in a compound of formula ##STR2## wherein X.sub.1 is a functionally modified phosphono group and X.sub.2 is a free or functionally modified phosphono group, X.sub.1 and, if appropriate X.sub.2, into the free phosphono group.Patent expiration dates:
- September 2, 2012✓✓✓
- March 2, 2013✓
- September 2, 2012
Pharmaceutical products comprising bisphosphonates
Patent 7,932,241
Issued: April 26, 2011
Inventor(s): Glausch; Alexandra & Löffler; Rolf & Sigg; Juergen
Assignee(s): Novartis AG
A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of a ready to use infusion solution, for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.Patent expiration dates:
- February 5, 2028✓
- February 5, 2028
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 20, 2011 - REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
- September 20, 2011 - PEDIATRIC EXCLUSIVITY
See also...
- Zometa Consumer Information (Drugs.com)
- Zometa Consumer Information (Wolters Kluwer)
- Zometa Consumer Information (Cerner Multum)
- Zometa Advanced Consumer Information (Micromedex)
- Zometa AHFS DI Monographs (ASHP)
- Zoledronic Acid Consumer Information (Wolters Kluwer)
- Zoledronic acid Consumer Information (Cerner Multum)
- Zoledronic acid Intravenous Advanced Consumer Information (Micromedex)
- Zoledronic Acid AHFS DI Monographs (ASHP)
